Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review
Open Access
- 1 June 2025
- journal article
- review article
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 557-565
Abstract
Combining cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) with cyclin-dependent proteins can reduce the formation of cyclin D-CDK4/6 complexes, resulting in the inactivation of downstream genes and suppression of cell proliferation. Previous research on the use of CDK4/6 inhibitors in combination with endocrine therapies and anti-HER2 targeting agents across various subtypes and stages of breast cancer has shown promising outcomes in patient prognoses and tolerable drugs toxicities. For the present, the CDK4/6 inhibitors that have been widely used for the treatment of breast cancer are palbociclib, abemaciclib and ribociclib. Dalpiciclib (SHR6390), a novel and selective CDK4/6 inhibitor developed in China, has been approved by the National Medical Products Administration. The researches about dalpiciclib with different anti-tumor drugs are ongoing to explore the efficacy and the best strategies to use dalpiciclib. This review provides an overview of the research progress on dalpiciclib across different breast cancer subtypes with various anti-tumor drugs in different treatment opportunities.Keywords
This publication has 86 references indexed in Scilit:
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3Annals of Oncology, 2024
- A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple‐positive breast cancerMedcomm, 2024
- CDK4/6 inhibitors induce breast cancer senescence with enhanced anti‐tumor immunogenic properties compared with DNA‐damaging agentsMolecular Oncology, 2023
- The role of CDK6 in cancerInternational Journal of Cancer, 2020
- Cyclin D-CDK4/6 functions in cancer2020
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2JAMA Oncology, 2020
- Breast Cancer TreatmentJAMA, 2019
- Cyclin D1, cancer progression, and opportunities in cancer treatmentJournal of Molecular Medicine, 2016
- The retinoblastoma protein and cell cycle controlCell, 1995
- Cyclin D1 protein expression and function in human breast cancerInternational Journal of Cancer, 1994